Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

The system is compatible with 1.5T and 3T magnetic resonance imaging scans and eliminates the need for an implanted battery.

The FDA has approved the Genio® system for treating patients with moderate to severe obstructive sleep apnea (OSA) with an ...

Genio is a different approach to hypoglossal nerve stimulation (HGNS) for the treatment of OSA. Genio’s unique design ...

Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S.

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

Investing.com -- Nyxoah SA (BR:NYXH) (NASDAQ: NYXH) stock jumped 9.4% following FDA approval of its Genio system for treating moderate to severe obstructive sleep apnea (OSA).

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East First patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates Mont-Saint-Guibert ...

Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing ...